Koch S, Haefner H, Huenger F, Haase G, Wildberger J, Lemmen S W
Zentralbereich für Krankenhaushygiene und Infektiologie, Universitätsklinikum Aachen, RWTH Aachen.
Anaesthesist. 2005 Oct;54(10):1047-64; quiz 1065-6. doi: 10.1007/s00101-005-0919-x.
Invasive fungal infections are associated with a high mortality and have been increasing in incidence over the last few decades. Candidemia and, less commonly, invasive pulmonary aspergillosis are the most relevant fungal infections in critical care medicine. Risk factors for systemic Candida infections are the use of broad-spectrum antibiotics, a prolonged stay in an intensive care unit and gastrointestinal injury or surgery. Invasive aspergillosis usually occurs in immunocompromised patients. The diagnosis of invasive fungal infections remains challenging. The therapeutic spectrum includes fluconazol, conventional and liposomal amphotericin B, and the recently introduced agents caspofungin and voriconazol. For rational and cost-effective use, the clinician requires precise knowledge of the indications and limitations of these agents. This review focuses on the diagnostic and therapeutic options in severe Candida infections and invasive aspergillosis.
侵袭性真菌感染与高死亡率相关,且在过去几十年中发病率不断上升。念珠菌血症以及较少见的侵袭性肺曲霉病是重症医学中最相关的真菌感染。全身性念珠菌感染的危险因素包括使用广谱抗生素、在重症监护病房长期住院以及胃肠道损伤或手术。侵袭性曲霉病通常发生在免疫功能低下的患者中。侵袭性真菌感染的诊断仍然具有挑战性。治疗药物包括氟康唑、传统和脂质体两性霉素B,以及最近引入的药物卡泊芬净和伏立康唑。为了合理且经济有效地使用这些药物,临床医生需要精确了解这些药物的适应证和局限性。本综述重点关注重症念珠菌感染和侵袭性曲霉病的诊断和治疗选择。